Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Elvira Favoino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Medicine, Rheumatic and Systemic Autoimmune Diseases Unit, University of Bari Medical School, Bari, Italy. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Scleroderma, Systemic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Italian Group against Systemic Sclerosis, GILS.
Abstract (Originalsprache)
Anti-centromere (ACA) and antimitochondrial antibodies (AMA) are specific for limited-cutaneous systemic sclerosis (lcSSc) and primary biliary cholangitis (PBC), respectively, and can coexist in up to 25 and 30% of SSc and PBC patients. Here, we evaluated whether anti-centromeric protein A (CENP-A) antibodies cross-react with mitochondrial antigens. To this end, sera from two lcSSc patients (pt1 and pt4), one of them (pt4) also affected by PBC, were used as the source of ACA, previously shown to recognize different groups of amino acids (motifs) in the CENP-A region spanning amino acids 1–17 (Ap1–17). Pt1 and pt4 Ap1–17-specific IgG were purified by affinity-chromatography on insolubilized Ap1–17-peptide column and tested by western blotting with nuclear and cytoplasmic protein extract from HeLa cells. Immunoreactive proteins were identified by mass spectrometry and validated by immunodot. The results showed that affinity-purified SSc/PBC pt4 anti-Ap1–17 and not SSc pt1 anti-Ap1–17 Ab, specifically cross-reacted with the E2 component of the mitochondrial pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen in PBC. Sequence homology analysis indicated that the motif A-x-x-P-x-A-P recognized by pt4 anti-Ap1–17 IgG and shared by CENP-A and PDC-E2, is also expressed by some members of the Human Herpesvirus family, suggesting that they may trigger the production of these cross-reacting antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interdisciplinary Medicine, Rheumatic and Systemic Autoimmune Diseases Unit, University of Bari Medical School, Bari, Italy.
- Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
- Department of Precision Medicine, Rheumatology Section, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy.
- Department of Biomedical Science and Human Oncology, Unit of Dermatology, University of Bari Medical School, Bari, Italy.
- Department of Medicine, Rheumatology and Immunology Unit, University of Rome "Campus Biomedico", Rome, Italy.
ORCID-Profile: Elvira Favoino
Förderung
- Italian Group against Systemic Sclerosis
- GILS
Zitieren
APA
Favoino, E., Grapsi, E., Barbuti, G., Liakouli, V., Ruscitti, P., Foti, C., Giacomelli, R., & Perosa, F. (2023). Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad012
Vancouver
Favoino E, Grapsi E, Barbuti G, Liakouli V, Ruscitti P, Foti C, et al. Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad012
BibTeX
@article{Favoino2023,
author = {Favoino, Elvira and Grapsi, Ettore and Barbuti, Giovanna and Liakouli, Vasiliki and Ruscitti, Piero and Foti, Caterina and Giacomelli, Roberto and Perosa, Federico},
title = {Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad012}
}
EUVIMED